In a small multi-institutional retrospective analysis of 37 patients with unresectable stage III EGFR-mutated NSCLC who received concurrent CRT, 13 initiated durvalumab within a median of 20 days after cCRT completion [84]. Here, EGFR is linked to non-small cell lung carcinoma.